Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a small molecule inhibitor designed to mimic the transition state of deacylation in beta-lactamase enzymes. It is specifically effective against TEM-1 beta-lactamase, with an inhibition constant of 13 nM, making it a potent competitive inhibitor[6][7].
- Other names
- 3-[(2R)-2-Acetamido-2-(dihydroxyboryl)ethyl]-2-hydroxybenzoic acidAcide 3-[(2R)-2-acétamido-2-(dihydroxyboryl)éthyl]-2-hydroxybenzoïqueBenzoic acid, 3-[(2R)-2-(acetylamino)-2-boronoethyl]-2-hydroxy-
02
Targets
CD248 (Endosialin)
Beyond the preview
Go deeper on 1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 1(R)-1-ACETAMIDO-2-(3-CARBOXY-2-HYDROXYPHENYL)ETHYL BORONIC ACID.